Hyaluronic Acid- Paclitaxel: Antitumor Efficacy against CD44(+) Human Ovarian Carcinoma Xenografts

Hyaluronic Acid- Paclitaxel: Antitumor Efficacy against CD44(+) Human Ovarian Carcinoma Xenografts

Numerous human tumor types, including ovarian cancer, display a significant expression of the CD44 family of cell surface proteoglycans. To develop tumortargeted drugs, we have initially evaluated whether the CD44 ligand hyaluronic acid (HA) could serve as a backbone for paclitaxel (TXL) prodrugs. H...

Full description

Bibliographic Details
Main Authors: Edmond Auzenne, Sukhen C. Ghosh, Mojgan Khodadadian, Belinda Rivera, David Farquhar, Roger E. Price, Murali Ravoori, Vikas Kundra, Ralph S. Freedman, Jim Klostergaard
Format: Article
Language:English
Published: Elsevier 2007-06-01
Series:Neoplasia: An International Journal for Oncology Research
Subjects:
Hyaluronic acid
CD44
paclitaxel
prodrug
human ovarian carcinoma
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558607800042

Internet

http://www.sciencedirect.com/science/article/pii/S1476558607800042

Similar Items